NASDAQ:RETA Reata Pharmaceuticals - RETA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Reata Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $87.78 -0.75 (-0.85%) (As of 03/28/2023 02:32 PM ET) Add Compare Share Share Today's Range$86.26▼$90.1450-Day Range$30.85▼$93.1752-Week Range$18.47▼$95.00Volume341,142 shsAverage Volume1.54 million shsMarket Capitalization$3.22 billionP/E RatioN/ADividend YieldN/APrice Target$95.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Reata Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside10.0% Upside$96.89 Price TargetShort InterestHealthy18.08% of Float Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews Sentiment0.89Based on 6 Articles This WeekInsider TradingSelling Shares$9.70 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($8.44) to ($8.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.65 out of 5 starsMedical Sector240th out of 1,002 stocksPharmaceutical Preparations Industry98th out of 488 stocks 3.4 Analyst's Opinion Consensus RatingReata Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $96.89, Reata Pharmaceuticals has a forecasted upside of 10.0% from its current price of $88.06.Amount of Analyst CoverageReata Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted18.08% of the float of Reata Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverReata Pharmaceuticals has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Reata Pharmaceuticals has recently decreased by 39.83%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldReata Pharmaceuticals does not currently pay a dividend.Dividend GrowthReata Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreReata Pharmaceuticals has received a 78.64% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Reata Pharmaceuticals is -0.75. Previous Next 3.3 News and Social Media Coverage News SentimentReata Pharmaceuticals has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Reata Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 103 people have searched for RETA on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.MarketBeat Follows19 people have added Reata Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 138% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Reata Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,704,843.00 in company stock.Percentage Held by Insiders28.70% of the stock of Reata Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.13% of the stock of Reata Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Reata Pharmaceuticals are expected to decrease in the coming year, from ($8.44) to ($8.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Reata Pharmaceuticals is -10.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Reata Pharmaceuticals is -10.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Reata Pharmaceuticals (NASDAQ:RETA) StockReata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX.Read More Receive RETA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RETA Stock News HeadlinesMarch 7, 2023 | marketbeat.comThe Stock That Tripled in a Day...And May Not Be DoneReata Pharmaceuticals now has a long-coveted commercialized drug in its portfolio. Should investors covet this biotech stock for their portfolios?March 27, 2023 | markets.businessinsider.comWhere Reata Pharmaceuticals Stands With AnalystsMarch 28, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.March 5, 2023 | businesswire.comREATA PHARMACEUTICALS INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Reata Pharmaceuticals, Inc ...March 3, 2023 | businesswire.comREATA PHARMACEUTICALS INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Reata Pharmaceuticals, Inc. - RETAMarch 2, 2023 | bizjournals.comPlano-based Reata Pharmaceuticals secures FDA approval for first-of-its-kind ultra-rare disease treatmentMarch 2, 2023 | finance.yahoo.comWhy Reata Pharmaceuticals Stock Skyrocketed This WeekMarch 2, 2023 | finance.yahoo.comReata (RETA) Stock Jumps as FDA Approves Rare Disease DrugMarch 28, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. March 1, 2023 | msn.comHot Stocks: RETA nearly triples on FDA approval; FSLR surges on earnings; NVAX, MQ plungeMarch 1, 2023 | reuters.comU.S. FDA approves Reata's rare genetic disorder drugMarch 1, 2023 | msn.comReata Skyrockets on FDA Approval for Friedreich’s Ataxia DrugMarch 1, 2023 | barrons.comReata Soars on Approval for Rare Disorder Drug. Its Pipeline Value Impresses Analysts.February 19, 2023 | nasdaq.comFirst Week of April 21st Options Trading For Reata Pharmaceuticals (RETA)February 1, 2023 | finance.yahoo.comThe Nasdaq Is Rebounding: 2 Supercharged Growth Stocks to Buy in FebruaryJanuary 25, 2023 | forbes.comReata PharmaceuticalsJanuary 14, 2023 | fool.comReata Pharmaceuticals (NASDAQ: RETA)December 31, 2022 | finance.yahoo.comReata Pharmaceuticals, Inc. (NASDAQ:RETA) Q3 2022 Earnings Call TranscriptDecember 31, 2022 | finance.yahoo.comReata Pharmaceuticals, Inc. (NASDAQ:RETA) Q3 2022 Earnings Call TranscriptDecember 22, 2022 | finance.yahoo.comReata Pharmaceuticals (NASDAQ:RETA) shareholders have endured a 84% loss from investing in the stock three years agoNovember 9, 2022 | finance.yahoo.comReata (RETA) Q3 Earnings Beat, Stock Up on Pipeline UpdatesNovember 8, 2022 | seekingalpha.comReata rises 15% as omaveloxolone moves ahead in FDA review process; plans EU filingNovember 8, 2022 | finance.yahoo.comWhy Reata Pharmaceuticals Stock Is Soaring TodayNovember 8, 2022 | finance.yahoo.comReata Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results and Provides an Update on Clinical Development ProgramsNovember 1, 2022 | finance.yahoo.comReata Pharmaceuticals, Inc. to Report Third Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on November 8, 2022October 31, 2022 | finance.yahoo.com2 On-Fire Biotech Stocks That Are Crushing the Bear MarketOctober 14, 2022 | investorplace.comWhy Is Reata Pharmaceuticals (RETA) Stock Up 15% Today?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RETA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RETA Company Calendar Last Earnings11/08/2021Today3/28/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RETA CUSIPN/A CIK1358762 Webwww.reatapharma.com Phone(972) 865-2219FaxN/AEmployees346Year Founded2002Price Target and Rating Average Stock Price Forecast$96.89 High Stock Price Forecast$138.00 Low Stock Price Forecast$67.00 Forecasted Upside/Downside+7.3%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($8.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-311,900,000.00 Net Margins-9,897.91% Pretax Margin-14,076.08% Return on Equity-922.50% Return on Assets-51.78% Debt Debt-to-Equity RatioN/A Current Ratio6.75 Quick Ratio6.75 Sales & Book Value Annual Sales$2.22 million Price / Sales1,464.73 Cash FlowN/A Price / Cash FlowN/A Book Value($1.79) per share Price / Book-49.46Miscellaneous Outstanding Shares36,730,000Free Float26,186,000Market Cap$3.25 billion OptionableOptionable Beta1.27 Social Links Key ExecutivesJ. Warren HuffChairman & Chief Executive OfficerManmeet Singh SoniPresident, Chief Operating & Financial OfficerW. Christian WigleyChief Scientific Officer & Senior Vice PresidentSamina KhanChief Medical Officer & Senior Vice PresidentDakota GallivanVP, Chief Healthcare & Compliance OfficerKey CompetitorsAmicus TherapeuticsNASDAQ:FOLDIVERIC bioNASDAQ:ISEECytokineticsNASDAQ:CYTKACADIA PharmaceuticalsNASDAQ:ACADZai LabNASDAQ:ZLABView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCSold 620 shares on 3/23/2023Ownership: 0.041%Shamim RuffSold 5,740 sharesTotal: $480,610.20 ($83.73/share)Andrea LoewenSold 19,036 sharesTotal: $1.59 M ($83.43/share)Bhaskar AnandSold 165 sharesTotal: $13,955.70 ($84.58/share)Dawn Carter BirSold 54,954 sharesTotal: $4.92 M ($89.56/share)View All Insider TransactionsView All Institutional Transactions RETA Stock - Frequently Asked Questions Should I buy or sell Reata Pharmaceuticals stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RETA shares. View RETA analyst ratings or view top-rated stocks. What is Reata Pharmaceuticals' stock price forecast for 2023? 6 Wall Street research analysts have issued 1-year price objectives for Reata Pharmaceuticals' stock. Their RETA share price forecasts range from $67.00 to $138.00. On average, they anticipate the company's stock price to reach $96.89 in the next year. This suggests a possible upside of 9.4% from the stock's current price. View analysts price targets for RETA or view top-rated stocks among Wall Street analysts. How have RETA shares performed in 2023? Reata Pharmaceuticals' stock was trading at $37.99 at the beginning of the year. Since then, RETA shares have increased by 133.0% and is now trading at $88.53. View the best growth stocks for 2023 here. Are investors shorting Reata Pharmaceuticals? Reata Pharmaceuticals saw a decrease in short interest in March. As of March 15th, there was short interest totaling 5,030,000 shares, a decrease of 39.8% from the February 28th total of 8,360,000 shares. Based on an average daily volume of 1,420,000 shares, the days-to-cover ratio is currently 3.5 days. Approximately 18.1% of the company's shares are short sold. View Reata Pharmaceuticals' Short Interest. How were Reata Pharmaceuticals' earnings last quarter? Reata Pharmaceuticals, Inc. (NASDAQ:RETA) announced its quarterly earnings data on Monday, November, 8th. The company reported ($1.97) EPS for the quarter, topping analysts' consensus estimates of ($2.32) by $0.35. The business earned $7.40 million during the quarter, compared to analyst estimates of $2.07 million. Reata Pharmaceuticals had a negative trailing twelve-month return on equity of 922.50% and a negative net margin of 9,897.91%. The company's revenue was up 428.6% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.94) EPS. What ETFs hold Reata Pharmaceuticals' stock? ETFs with the largest weight of Reata Pharmaceuticals (NASDAQ:RETA) stock in their portfolio include Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco DWA Healthcare Momentum ETF (PTH), SPDR S&P Pharmaceuticals ETF (XPH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Nasdaq Future Gen 200 ETF (QQQS), iShares U.S. Pharmaceuticals ETF (IHE), Principal Healthcare Innovators ETF (BTEC) and Invesco Nasdaq Biotechnology ETF (IBBQ). What is Warren Huff's approval rating as Reata Pharmaceuticals' CEO? 10 employees have rated Reata Pharmaceuticals Chief Executive Officer Warren Huff on Glassdoor.com. Warren Huff has an approval rating of 92% among the company's employees. This puts Warren Huff in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Reata Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Synlogic (SYBX), NVIDIA (NVDA), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO) and Archrock (AROC). When did Reata Pharmaceuticals IPO? (RETA) raised $60 million in an initial public offering on Thursday, May 26th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray served as the underwriters for the IPO. What is Reata Pharmaceuticals' stock symbol? Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA." Who are Reata Pharmaceuticals' major shareholders? Reata Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include First Light Asset Management LLC (5.63%), Fred Alger Management LLC (4.12%), Deutsche Bank AG (4.07%), Boxer Capital LLC (3.36%), Morgan Stanley (2.00%) and Emerald Advisers LLC (1.86%). Insiders that own company stock include Andrea Loewen, Bhaskar Anand, Colin John Meyer, Dawn Carter Bir, Elaine Castellanos, James Warren Huff, Manmeet Singh Soni, Michael D Wortley, Samina Khan and Shamim Ruff. View institutional ownership trends. How do I buy shares of Reata Pharmaceuticals? Shares of RETA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Reata Pharmaceuticals' stock price today? One share of RETA stock can currently be purchased for approximately $88.53. How much money does Reata Pharmaceuticals make? Reata Pharmaceuticals (NASDAQ:RETA) has a market capitalization of $3.25 billion and generates $2.22 million in revenue each year. The company earns $-311,900,000.00 in net income (profit) each year or ($8.56) on an earnings per share basis. How many employees does Reata Pharmaceuticals have? The company employs 346 workers across the globe. How can I contact Reata Pharmaceuticals? Reata Pharmaceuticals' mailing address is 5320 LEGACY DRIVE, PLANO TX, 75024. The official website for the company is www.reatapharma.com. The company can be reached via phone at (972) 865-2219 or via email at ir@reatapharma.com. This page (NASDAQ:RETA) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.